助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   metabolism factors 的翻译结果: 查询用时:0.008秒
图标索引 在分类学科中查询
所有学科
更多类别查询

图标索引 历史查询
 

metabolism factors
相关语句
  代谢因素
     Objective To study the relationship between systemic lupus erythematosus(SLE) and plasma homocysteine(Hcy) and analyze metabolism factors of Hcy in SLE.
     目的 探讨系统性红斑狼疮(SLE)与血浆同型半胱氨酸(Hcy)间的关系,并分析影响SLE患者Hcy的代谢因素
短句来源
     (4) Some metabolism factors may alter the sensitivity of bacteria to quinolones.
     ( 4 )细菌的其他一些代谢因素也可影响喹诺酮类的抑菌作用。
短句来源
  “metabolism factors”译为未确定词的双语例句
     CHANGES OF METABOLISM FACTORS IN DIFFERENTIATION OF HEPG2 CELLS INDUCED BY MATRINE
     苦参碱诱导HepG2细胞分化相关代谢指征的变化
短句来源
     A Laboratory Study on KOA Experiment Model Change in Matrix Metabolism Factors Using Different Kinds of Acupuncture Treatment
     针刺、电针和温针治疗对膝骨性关节炎(KOA)软骨基质代谢调节作用的实验研究
短句来源
     3. Uric acid calculus patients, calcium oxalate and none urinary calculus patients who have undergone analysis of metabolic evaluation. The results of uric acid calculus patients compared to another two groups to analysis the relations between the formation of uric acid calculus and metabolism factors.
     3.分别对确诊的尿酸结石患者、草酸钙患者和正常人进行广泛式代谢评估,包括血清学检查(钠、钾、氯、钙、磷、镁、尿酸、肌酐)、尿液常规检查(尿常规、尿pH值)及24h尿定量分析(尿量、尿钠、钙、磷、尿酸、尿枸橼酸、尿草酸),并行组间比较,分析尿酸结石形成的代谢性因素。
短句来源
     This paper sums up the metabolism,factors determining the absorption and bio- logical functions of zinc,thus providing a reference for researches and application of Zinc in nutrition.
     本文综述了锌的代谢,锌吸收的影响因素和锌的生物学功能,为锌营养研究和应用提供参考。
短句来源
  相似匹配句对
     The factors.
     其中外界因素的影响最为重要。
短句来源
     Metabolism of Antiarrhythmic Drugs and its Affecting Factors
     抗心律失常药物体内代谢及其临床影响因素
短句来源
     The factors effecting the metabolism of isoflavones were discussed in details.
     还着重地论述了影响异 黄酮代谢的因素,包括代谢应答、吸收以及排泄等。
短句来源
     METABOLISM OF FARREROL
     杜鹃素的体内代谢
短句来源
     and(c)influencing factors.
     ③资本结构影响因素研究。
短句来源
查询“metabolism factors”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
没有找到相关例句


Study 1 Changes in blood drug level, metabolism, and pharmacokinetics of scu PA and tcu PA were investigated in a double control and cross over study in monkeys following intravenous injections of rhprouk (0.4 mg/kg, 0.8 mg/kg and 3.2 mg/kg) and un UK (1.28×10 5 IU/Kg). A 10% dose of the total drug was injected intravenously and the remaining 85% was infused intravenously within 90 min. In all groups of rhprouk injection, we found that the increases in blood levels of u PA and scu PA were positively...

Study 1 Changes in blood drug level, metabolism, and pharmacokinetics of scu PA and tcu PA were investigated in a double control and cross over study in monkeys following intravenous injections of rhprouk (0.4 mg/kg, 0.8 mg/kg and 3.2 mg/kg) and un UK (1.28×10 5 IU/Kg). A 10% dose of the total drug was injected intravenously and the remaining 85% was infused intravenously within 90 min. In all groups of rhprouk injection, we found that the increases in blood levels of u PA and scu PA were positively correlated with the doses of rhprouk. The in vivo production of tcu PA was dependent on the doses of rhprouk and the blood levels of scu PA. A significant increase in tcu PA blood level was only noted after rhprouk injection at 3.2 mg/Kg. On the other hand, the un UK injection induced only an increase in blood u PA level, while the blood scu PA level was constantly below LOQ. A significant variation was found in the drug clearance curves of u PA, scu PA and tcu PA among individual dose group of rhprouk within the 90 min infusion interval. The initial dose of intravenous injection (mg) and the dose rate of the intravenous infusion (μg/min) were critical in maintaining the blood levels of drugs. In rhprouk dose group of 0.4 mg/kg, the decrease in blood scu PA level was found to stabilize at 1 100 ng/mL within the infusion interval. In rhpro UK dose group of 0.8 mg/kg, the blood scu PA levels were maintained at 2 000 ng/mL within the infusion interval (infusion dose rate 9 μg/min). No significant metabolism from scu PA to tcu PA was found in this dose group, and a balance between the drug infusion and clearance was noted during the infusion. In rhprouk dose group of 3.2 mg/kg, the metabolism from scu PA to tcu PA was greatly increased, and we noted a steady increase in blood scu PA which plateaued between 3 000~7 000 ng/mL. These findings revealed that clinical treatment of rhprouk at 3.2 mg/kg was essential to maintain an optimal scu PA level in blood without causing excessive metabolism to tcu PA. In the dose groups of 0.4 mg/kg, 0.8 mg/kg and 3.2 mg/kg, the corresponding post infusion AUC (0.5 5h) of the blood scu PA levels were (2?140±540), (3?880±690) and (8?290±2?480) ng/(h·mL) ( p < 0.05) respecfively. The AUC (0.5 5h) of the blood total u PA levels were (2?320±500), (4?140±710) and (17?420± 3?110) ng/(h·mL), respectively ( P < 0.01 to P < 0.05). The AUC (0.5 5h) of the blood tcu PA levels were (180±60), (270±40) and (913±525) ng/(h·mL), respectively ( P < 0.05). Thus it is estimated from the blood AUC tcu PA /AUC u PA ratio that tcu PA production rates were 7.7 %, 6.5 % and 52.4% in respective dose group ( P < 0.05). Our data indicated that the in vivo production of tcu PA was dependent on the dose of rhprouk treatment and blood scu PA levels. It was possible that the active molecules in rhprouk treatment at 0.4 and 0.8 mg/kg were mainly prototype scu PA. The side effect of hemorrhage during rhprouk treatment at doses larger than 0.8 mg/kg could be attributed to the production of tcu PA in vivo. In the dose groups of 0.4 mg/kg, 0.8 mg/kg and 3.2 mg/kg, the corresponding post infusion Cmax of scu PA were (1 300±40), (2 730±340) and (6 320±1 040) ng/mL ( P < 0.05) respectively. The ( rapid phase half life (t 1/2 ) of rhprouk was approximately (8.6±8.6) h, (7.9±5.5) h and (6.0±5.2) h, respectively. The end phase t 1/2 were ( 3.3 ±0.8) h, (3.1±0.5) h and (2.4±0.4) h, respectively. No significant statistic difference in t 1/2 was noted amang dose groups. The longer t 1/2 observed in dose group 3.2 mg/kg was possibly linked to metabolism factors. Study 2 We have studied the tissue total radioactivity, TCA acid base radioactivity and TCA acid base radioactivity/tissue total radioactivity ratio at 10 min, 100 min, 5.5 h and 48 h after intravenous application of 0.8 mg/kg 125 I rhprouk (radioactive strength 2.506 MBq/mg) in rabbits. An initial 15 % of the total dos

第一部分 :采用交叉设计 ,自身比较 ,研究了猕猴静脉注射 0 .4 ,0 .8和 3.2mg·kg- 1 重组人尿激酶原 (rhprouk)或 1.2 8× 10 5IU·kg- 1 尿源性天然尿激酶 (un UK) (其中推注 15 %剂量 ,90min内恒速滴注 85 %剂量 )后血浆中单链尿激酶型纤溶酶原激活剂 (scu PA)和双链尿激酶型纤溶酶原激活剂 (tcu PA)的浓度随时间变化、代谢转化和各自的药代动力学 ,及代谢转化和药代动力学参数与剂量浓度的依赖关系 .结果表明给药后scu PA转化为tcu PA的速度与scu PA的剂量呈正相关性 .第二部分 :通过测定兔静脉推注加滴注1 2 5I rhprouk 0 .8mg·kg- 1 (其中 15 %剂量静脉推注 ,85 %剂量在 90min内滴注 ,比放射活性 2 .5 0 6MBq/mg)后不同时间体内各组织总放射性、TCA酸沉放射性 ,以及酸沉和总放射性的比值 ;胆汁引流物放射性累计排出量 ,尿和粪中累计排出量 ,及在体内外1 2 5I rhprouk与血浆蛋白的结合 .研究rhprouk在体内的分布、代谢及排泄情况 .结果表明rhpro...

第一部分 :采用交叉设计 ,自身比较 ,研究了猕猴静脉注射 0 .4 ,0 .8和 3.2mg·kg- 1 重组人尿激酶原 (rhprouk)或 1.2 8× 10 5IU·kg- 1 尿源性天然尿激酶 (un UK) (其中推注 15 %剂量 ,90min内恒速滴注 85 %剂量 )后血浆中单链尿激酶型纤溶酶原激活剂 (scu PA)和双链尿激酶型纤溶酶原激活剂 (tcu PA)的浓度随时间变化、代谢转化和各自的药代动力学 ,及代谢转化和药代动力学参数与剂量浓度的依赖关系 .结果表明给药后scu PA转化为tcu PA的速度与scu PA的剂量呈正相关性 .第二部分 :通过测定兔静脉推注加滴注1 2 5I rhprouk 0 .8mg·kg- 1 (其中 15 %剂量静脉推注 ,85 %剂量在 90min内滴注 ,比放射活性 2 .5 0 6MBq/mg)后不同时间体内各组织总放射性、TCA酸沉放射性 ,以及酸沉和总放射性的比值 ;胆汁引流物放射性累计排出量 ,尿和粪中累计排出量 ,及在体内外1 2 5I rhprouk与血浆蛋白的结合 .研究rhprouk在体内的分布、代谢及排泄情况 .结果表明rhprouk不与血浆中蛋白结合 ,代谢部位主要集中在胆、肾等部位 ,代谢产物主要随小便排出 .

The principal component analysis was conducted on the agronomic characters, physiological indexes that had a closely relation with wheat yield at different types wheat varieties (lines). Eleven primitive indexes could be synthesized into 3 new independent indexes:principal component1 (Z 1),Principal component2 (Z 2) and principal component3 (Z 3). They individually mean "photosynthesis assimilation factor", "sink and carbohydrate and nitrogen metabolism factor", and "sink and nitrogen nutrient...

The principal component analysis was conducted on the agronomic characters, physiological indexes that had a closely relation with wheat yield at different types wheat varieties (lines). Eleven primitive indexes could be synthesized into 3 new independent indexes:principal component1 (Z 1),Principal component2 (Z 2) and principal component3 (Z 3). They individually mean "photosynthesis assimilation factor", "sink and carbohydrate and nitrogen metabolism factor", and "sink and nitrogen nutrient factor". The result of the correlation analysis about the principal component values and yields showed that, Z 1 and Z 2 had a closely positive correlation with the yields. Regress equation about the yield and principal component values was built by using the Regression Analysis. It could better showed the yield levels of the different varieties.

本文对不同类型小麦品种 (系 )的 11个与产量密切相关的农艺性状、生理指标进行了主成分分析。 11个原始指标综合成为三个独立的新指标 ,分别表示“光合同化因子”、“库与碳氮代谢因子”、“库与氮素营养因子”。主成分值与产量相关分析表明 ,小麦产量与第一、第二主成分值有极显著正相关关系。通过回归分析 ,建立了小麦产量与主成分值之间的回归方程。它能较好地反映不同类型品种的产量水平

Quinolones are antibiotics widely used in clinics. However, resistance to quinolones in pathogenic bacteria occurs at times. This article reviews the main mechanisms that bacteria develop to counteract quinolones. (1) Generally, Quinolones disturb bacterial DNA replication by binding topoisomerase type Ⅱ. Therefore, mutants with variation of topoisomerase type Ⅱ can evade the inhibition of quinolones. High level quinolone resistance require mutations in both DNA gyrase gene and topoisomerase Ⅳ gene. (2) Bacterial...

Quinolones are antibiotics widely used in clinics. However, resistance to quinolones in pathogenic bacteria occurs at times. This article reviews the main mechanisms that bacteria develop to counteract quinolones. (1) Generally, Quinolones disturb bacterial DNA replication by binding topoisomerase type Ⅱ. Therefore, mutants with variation of topoisomerase type Ⅱ can evade the inhibition of quinolones. High level quinolone resistance require mutations in both DNA gyrase gene and topoisomerase Ⅳ gene. (2) Bacterial cell wall is the barrier for the entry of antibiotics. Certain changes of outer membrane components, such as lipopolysaccharide and porins, can reduce the permeation of quinolones. (3) Some bacteria can pump quinolones out by themselves, so that concentration of quinolones within them would be lower. (4) Some metabolism factors may alter the sensitivity of bacteria to quinolones.

喹诺酮类是目前临床上应用较多的抗菌药。然而 ,喹诺酮类耐药菌时有出现。就细菌对喹诺酮类抗菌药主要耐药机制从分子水平作一综述。 ( 1 )一般认为 ,喹诺酮类抗菌药通过结合细菌Ⅱ类拓扑异构酶 ,干扰细菌复制 ,而发挥抑菌作用。Ⅱ类拓扑异构酶变异时 ,细菌可逃脱喹诺酮类的抑菌作用。高水平的耐药由DNA回旋酶和拓扑异构酶Ⅳ同时发生变异造成。 ( 2 )细菌细胞壁是抗菌药进入的屏障。细胞壁组分脂多糖和孔蛋白的改变 ,可减少喹诺酮类的通透。 ( 3)有些细菌可利用“外排泵”主动将喹诺酮类排出 ,降低喹诺酮类在菌体内的积累浓度。 ( 4 )细菌的其他一些代谢因素也可影响喹诺酮类的抑菌作用。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关metabolism factors的内容
在知识搜索中查有关metabolism factors的内容
在数字搜索中查有关metabolism factors的内容
在概念知识元中查有关metabolism factors的内容
在学术趋势中查有关metabolism factors的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社